Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · GLAXO

GLAXOSMITH

HealthcarePharmaceuticals & Biotechnology₹44689 cr market cap
₹2714.00 ▲ +2.87% today As of 19 Nov 2026
52-week low ₹2103.2052-week high ₹3106.40

-15.1% from the 52-week high · +25.4% above the low

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 3,680 full-time employees. The firm is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. The company manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. The company offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.

The short version. GLAXOSMITH reported revenue of ₹1,184 crore for Sep 2026, up 20.8% from a year earlier. Net profit was ₹336 crore (up 30.7% year on year). Return on equity was 45.7% in Mar 2026. Promoter holding was 75.0% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

GLAXOSMITH trades 15.1% below its 52-week high and 25.4% above its 52-week low.

Change over period: —

1M+5.7%
3M-13.0%
6M+12.4%
1Y+6.0%

2 · The business

Is it growing?

Sales, year on year+20.8%

Sep 2026 revenue of ₹1,184 cr.

Profit, year on year+30.7%

Sep 2026 net profit of ₹336 cr.

Net margin28.4%

2.1 pts higher than a year earlier.

3-year growth19.3% profit

Revenue compounded at 5.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue11849389951041980805974949
Net profit336237278296257205263230
Net margin %28.425.327.928.426.325.527.024.2
EPS (₹)19.8314.016.417.4515.212.115.5213.57

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue38223749345432523278319932243128
Net profit1036928590611169535893445
Net margin %27.124.717.118.851.711.22.914.2
EPS (₹)61.1554.7534.8336.05100.0421.145.526.29

3 · The quality

How well does it turn capital into profit?

Return on equity was 45.7% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %45.747.533.235.1
Return on capital %55.457.240.341.9
EBITDA margin %37.234.124.827.0
Net margin %26.123.816.518.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR5.8%3.7%
Profit CAGR19.3%23.7%
Debt to equity0.00
Interest cover516.0x
Current ratio2.13
P/E ratio39.0

4 · The owners

Who holds it, and are they adding?

Promoter holding75.0%

Unchanged over 8 quarters.

Foreign institutions4.75%

Up 0.25 pts over 8 quarters.

Domestic institutions8.48%

Up 1.18 pts over 8 quarters.

Mutual fund schemes144

+32 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter75.075.075.075.075.075.075.075.00.0
FII4.54.524.894.84.644.624.794.75+0.25
DII7.37.797.77.757.77.687.88.48+1.18
Public13.1912.6912.4112.4512.6612.6912.4111.77-1.42

Mutual fund holdings · Oct 2026

144 schemes hold this stock

112 the month before.

  • quant Healthcare Fund8.89% of NAV
  • Bandhan Healthcare Fund3.07% of NAV
  • quant Mid Cap Fund2.97% of NAV
  • Baroda BNP Paribas Dividend Yield Fund2.83% of NAV
  • NIPPON INDIA PHARMA FUND2.83% of NAV
  • quant Dynamic Asset Allocation Fund2.61% of NAV
  • DSP Nifty Midcap 150 Qlty 50 Index Fund2.35% of NAV
  • DSP NIFTY MIDCAP 150 QUALITY 50 ETF2.35% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for GLAXOSMITH are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about GLAXOSMITH

What is the GLAXOSMITH share price?

GLAXOSMITH (GLAXO) last closed at ₹2,714.00, up 2.87% on the day. Its 52-week range is ₹2,103.20 to ₹3,106.40.

What is the market cap of GLAXOSMITH?

GLAXOSMITH has a market capitalisation of about ₹44,689 crore. Its price-to-earnings ratio is 39.0.

How are GLAXOSMITH's latest results?

GLAXOSMITH reported revenue of ₹1,184 crore for Sep 2026, up 20.8% from a year earlier. Net profit was ₹336 crore (up 30.7% year on year). Return on equity was 45.7% in Mar 2026. Promoter holding was 75.0% in Sep 2026, up 0.00 points over 8 quarters.

Who owns GLAXOSMITH?

As of Sep 2026, shareholding was: Promoter 75.0%, FII 4.75%, DII 8.48%, Public 11.77%.

How many mutual funds hold GLAXOSMITH?

144 mutual fund schemes held GLAXOSMITH in October 2026. That compares with 112 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 29 May 2026 · Final Dividend - Rs. 57
  • 30 May 2025 · Final Dividend - Rs. 42
  • 07 Nov 2024 · Interim Dividend - Rs. 12
  • 31 May 2024 · Final Dividend - Rs. 32
  • 30 Jun 2023 · Final Dividend - Rs. 32
  • 07 Jul 2022 · Special Dividend - Rs. 60

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.